Pharma Report 2012: Get Back in Shape

Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

20    Forest Laboratories    $5.2B     up 10.6%
Global revenue*: $4.2B (20th); up 7.7%

R&D spend*: $716M (19th), down 34.9%; 17.0% of rev.

Top brands: Lexapro ($2.9B), Namenda ($1.5B), Bystolic ($383M)

Planned launches: Aclidinium (COPD), ­linaclotide (IBS)

Promotional spend: $866M (9th); 17.5% of rev.

Patent expirations: Lexapro (2012), Namenda (2015)

Forest's top-selling drug, $2.9-billion SSRI Lexapro, just lost patent protection, and number two drug Namenda's next in 2015. On the other other hand, there's the boffo sideshow that is longtime chief Howard Solomon's ongoing battles with (some would say persecution by) HHS and activist investor Carl Icahn. The upside is the company launched Teflaro in March, following Daliresp and Viibryd, and has already filed NDAs for aclidinium (COPD) and linaclotide (IBS).
* Global revenue and R&D spend are based on the fiscal year ending March 31, 2011, the latest data available at press time.

Back to first page

Page 20 of 21
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.